BACKGROUND: Newcastle disease virus (NDV) is a paramyxovirus that is pathogenic in birds but causes only mild flulike symptoms in human beings. NDV(F3aa)-GFP is a genetically modified, fusogenic NDV. We assessed the utility of NDV(F3aa)-GFP in treating head and neck squamous cell carcinoma. METHODS AND RESULTS: At a multiplicity of infection (MOI) of 1, NDV(F3aa)-GFP infection of 3 cell lines supported strong GFP expression by 36 hours. Four cell lines were highly sensitivite to viral cytotoxicity, with >75% of cells lysed by day 6 at MOI 0.1, and 2 other cell lines were partially susceptible. Murine SCC25 flank tumors exhibited robust GFP expression after a single intratumoral viral injection and showed near-complete tumor regression over 34 days. There were no adverse effects attributable to therapy. CONCLUSIONS: We demonstrate that a fusogenic NDV exerts potent oncolytic effects against human head and neck cancer and support its continued investigation for clinical application.
BACKGROUND:Newcastle disease virus (NDV) is a paramyxovirus that is pathogenic in birds but causes only mild flulike symptoms in human beings. NDV(F3aa)-GFP is a genetically modified, fusogenic NDV. We assessed the utility of NDV(F3aa)-GFP in treating head and neck squamous cell carcinoma. METHODS AND RESULTS: At a multiplicity of infection (MOI) of 1, NDV(F3aa)-GFP infection of 3 cell lines supported strong GFP expression by 36 hours. Four cell lines were highly sensitivite to viral cytotoxicity, with >75% of cells lysed by day 6 at MOI 0.1, and 2 other cell lines were partially susceptible. Murine SCC25flank tumors exhibited robust GFP expression after a single intratumoral viral injection and showed near-complete tumor regression over 34 days. There were no adverse effects attributable to therapy. CONCLUSIONS: We demonstrate that a fusogenic NDV exerts potent oncolytic effects against humanhead and neck cancer and support its continued investigation for clinical application.
Authors: K W Reichard; R M Lorence; C J Cascino; M E Peeples; R J Walter; M B Fernando; H M Reyes; J A Greager Journal: J Surg Res Date: 1992-05 Impact factor: 2.192
Authors: Man-Seong Park; John Steel; Adolfo García-Sastre; David Swayne; Peter Palese Journal: Proc Natl Acad Sci U S A Date: 2006-05-22 Impact factor: 11.205
Authors: R M Lorence; K W Reichard; B B Katubig; H M Reyes; A Phuangsab; B R Mitchell; C J Cascino; R J Walter; M E Peeples Journal: J Natl Cancer Inst Date: 1994-08-17 Impact factor: 13.506
Authors: M K Wallack; M Sivanandham; C M Balch; M M Urist; K I Bland; D Murray; W A Robinson; L Flaherty; J M Richards; A A Bartolucci; L Rosen Journal: J Am Coll Surg Date: 1998-07 Impact factor: 6.113
Authors: Zhenkun Yu; Sen Li; Peter Brader; Nanhai Chen; Yong A Yu; Qian Zhang; Aladar A Szalay; Yuman Fong; Richard J Wong Journal: Mol Cancer Date: 2009-07-06 Impact factor: 27.401
Authors: Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Natalya Chernichenko; Gary Linkov; Pingdong Li; Richard L Bakst; Chun-Hao Chen; Shuangba He; Yong A Yu; Nanhai G Chen; Aladar A Szalay; Yuman Fong; Richard J Wong Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-02 Impact factor: 6.223
Authors: Pascal Buijs; Stefan van Nieuwkoop; Vincent Vaes; Ron Fouchier; Casper van Eijck; Bernadette van den Hoogen Journal: Viruses Date: 2015-06-11 Impact factor: 5.048